Traws Pharma (TRAW)
NASDAQ:TRAW
Want to see TRAW full AI Analyst Report?
TRAW Stock Chart & Stats
$1.25
-$0.87(-9.63%)
At close: 4:00 PM EST
$1.25
-$0.87(-9.63%)
Day’s Range― - ―
52-Week Range$1.00 - $3.27
Previous CloseN/A
Volume35.69K
Average Volume (3M)206.36K
Market Cap
$24.54M
Enterprise Value$10.49M
Total Cash (Recent Filing)$3.13M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.27
Next Earnings
Aug 06, 2026EPS Estimate
-0.81Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.98
Shares Outstanding15,150,669
10 Day Avg. Volume403,079
30 Day Avg. Volume206,356
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-14.78
Price to Sales (P/S)3.33
P/FCF Ratio-0.45
Enterprise Value/Market Cap0.43
Enterprise Value/Revenue3.84
Enterprise Value/Gross Profit3.84
Enterprise Value/Ebitda-0.68
Forecast
1Y Price Target
$8.00Price Target Upside540.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-3.14
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Proof-of-concept For Second AntiviralHaving Phase 2a proof-of-concept for ratutrelvir is a durable de-risking event: a second clinical-stage asset broadens the company’s development optionality, strengthens partnering and licensing leverage, and demonstrates translational validity of its antiviral approach beyond preclinical models.
Next‑generation Tablet With Higher ExposureA formulation that raises exposure ~30% and supports once‑monthly dosing is a structural product advantage: it can materially improve adherence, market differentiation, and commercial attractiveness for prophylactic use, reducing long-term dosing complexity and strengthening competitive positioning.
Access To Contingent Capital And No DebtA closed PIPE with up to $60M in structured proceeds plus a no‑debt balance sheet improves near‑term financial flexibility. Milestone‑tied capital aligns funding with program milestones and, combined with absence of debt, lowers refinancing pressure and supports execution of planned trials into 2027.
Bears Say
FDA IND Clinical HoldAn FDA clinical hold for toxicology is a material structural risk: it can meaningfully delay U.S. development timelines, require additional preclinical work, increase program costs, and complicate global regulatory alignment, all of which lengthen time to pivotal data and commercialization.
Severe Cash Burn And Liquidity ReliancePersistently negative operating and free cash flow, a steep year‑over‑year cash decline, and dependence on milestone warrants create a structural funding vulnerability. If milestones are delayed or warrants not exercised, the company will face dilution or funding shortfalls that impair sustained R&D execution.
Earnings Quality And Negative EquityReported profitability in 2025 reflects non‑recurring accounting items and deferred revenue rather than cash‑generating operations; combined with negative equity, this signals accumulated losses and weak capital base, limiting strategic flexibility and raising long‑term solvency concerns.
Traws Pharma News
TRAW FAQ
What was Traws Pharma’s price range in the past 12 months?
Traws Pharma lowest stock price was $0.99 and its highest was $3.27 in the past 12 months.
What is Traws Pharma’s market cap?
Traws Pharma’s market cap is $24.54M.
When is Traws Pharma’s upcoming earnings report date?
Traws Pharma’s upcoming earnings report date is Aug 06, 2026 which is in 76 days.
How were Traws Pharma’s earnings last quarter?
Traws Pharma released its earnings results on May 15, 2026. The company reported -$0.53 earnings per share for the quarter, beating the consensus estimate of -$0.56 by $0.03.
Is Traws Pharma overvalued?
According to Wall Street analysts Traws Pharma’s price is currently Undervalued.
Does Traws Pharma pay dividends?
Traws Pharma does not currently pay dividends.
What is Traws Pharma’s EPS estimate?
Traws Pharma’s EPS estimate is -0.81.
How many shares outstanding does Traws Pharma have?
Traws Pharma has 15,150,669 shares outstanding.
What happened to Traws Pharma’s price movement after its last earnings report?
Traws Pharma reported an EPS of -$0.53 in its last earnings report, beating expectations of -$0.56. Following the earnings report the stock price went up 15.337%.
Which hedge fund is a major shareholder of Traws Pharma?
Currently, no hedge funds are holding shares in TRAW
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Traws Pharma
Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
TRAW Stock 12 Month Forecast
Average Price Target
$8.00
▲(540.00% Upside)
Technical Analysis
Ownership Overview
12.55% Insiders
0.74% Mutual Funds
20.94% Other Institutional Investors
65.40% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---